BACKGROUND: Image-guided radiotherapy (IGRT) is a novel technology to enhance RT delivery accuracy. However, the clinical effectiveness and cost-effectiveness are less clear. The aim of our study is to compare the cost and effectiveness of conventional fractionated RT for non-operated @entity2 delivered with vs. without IGRT via this population-based propensity score (PS) matched analysis. METHODS: We identified eligible @entity1 diagnosed within 2007-2010 through a comprehensive population-based database containing @entity5 , @entity204 registries, and reimbursement data in Taiwan. The primary duration of interest (DOI) was 2 years within diagnosis. Effectiveness was measured as survival whereas direct medical cost was measured from the payers' perspective. In supplementary analysis (SA), we estimated the cost-effectiveness in consider of out-of-pocket (OOP) payment and 4 years as DOI. RESULTS: Our study population constituted 124 @entity1 . Within 2 years, both the mean cost (2014 USD) and survival (life-year, LY) were higher for IGRT ( 60,774 vs.  60,554; 1.43 vs. 1.37). The incremental cost-effectiveness ratio (ICER) when IGRT was compared to non-IGRT was 3,667 (USD/LY). The chance for IGRT to be cost-effective was around 68% _ 70% at willingness-to-pay threshold 50,000 USD/LY and 150,000 USD/LY respectively. IGRT remained cost-effective in SA. CONCLUSIONS: We provide the first empirical evidence that when compared to non-IGRT, IGRT was potentially cost-effective.

Cost and effectiveness of image-guided radiotherapy for non-operated XXXX : a population-based propensity score-matched analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2 :: ('MESH:D008175', 'Disease') :: ['localized lung cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']
@entity2 :: (MESH:D008175,Disease) :: ['localized lung cancer']
